ARTICLE | Clinical News
Perifosine: Preliminary Phase II data
December 13, 2010 8:00 AM UTC
Preliminary data from an ongoing Phase II trial in 26 patients showed that twice-daily 50 mg perifosine for 28 days led to a partial response in 4 of 4 patients with chronic lymphocytic leukemia (CLL)...